Document:

Exhibit
10.30

 

First
LOAN MODIFICATION AGREEMENT

 

This
First Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of January 3, 2020, by and
among (a) SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa
Clara, California 95054 (“Bank”) and (b) (i) MISONIX, INC., a Delaware corporation (“Parent”),
(ii) MISONIX OPCO, INC., a New York corporation (“Misonix”), and (iii) SOLSYS MEDICAL, LLC, a
Delaware limited liability company (“Solsys”) (Parent, Misonix and Solsys are hereinafter jointly and severally,
individually and collectively, “Borrower”).

 

1.
DESCRIPTION OF EXISTING INDEBTEDNESS AND OBLIGATIONS. Among other indebtedness and obligations which may be owing by Borrower
to Bank, Borrower is indebted to Bank pursuant to a loan arrangement dated as of December 26, 2019, evidenced by, among other
documents, a certain Loan and Security Agreement dated as of December 26, 2019 (as may be amended, modified, restated, replaced
or supplemented from time to time the “Loan Agreement”). Capitalized terms used but not otherwise defined herein shall
have the same meaning as in the Loan Agreement.

 

2.
DESCRIPTION OF COLLATERAL. Repayment of the Obligations is secured by, among other property, (a) the Collateral as defined
in the Loan Agreement, (b) the Intellectual Property Collateral as defined in a certain Intellectual Property Security Agreement
dated as of December 26, 2019 between Parent and Bank (as amended, the “Parent Intellectual Property Security Agreement”),
(c) the Intellectual Property Collateral as defined in a certain Intellectual Property Security Agreement dated as of December
26, 2019 between Misonix and Bank (as amended, the “Misonix Intellectual Property Security Agreement”) and (d) the
Intellectual Property Collateral as defined in a certain Intellectual Property Security Agreement dated as of December 26, 2019
between Solsys and Bank (as amended, the “Solsys Intellectual Property Security Agreement”) (together with any other
collateral security granted to Bank, the “Security Documents”). Hereinafter, the Security Documents, together with
all other documents evidencing or securing the Obligations shall be referred to as the “Existing Loan Documents”.

 

3.
DESCRIPTION OF CHANGE IN TERMS.

 

	 	A.	Modification to Loan Agreement. The Loan Agreement
shall be amended by deleting the following text, appearing in Section 2.5 thereof:

 

“
(a) Commitment Fee. A fully earned, non-refundable commitment fee of One Hundred Thousand Dollars ($100,000.00), on the
Effective Date;”

 

and
inserting in lieu thereof the following:

 

“
(a) Commitment Fee. A fully earned, non-refundable commitment fee of Twenty Five Thousand Dollars ($25,000.00), on January
3, 2020;”

 

4.
FEES AND EXPENSES. Borrower shall reimburse Bank for all legal fees and expenses incurred in connection with this amendment
to the Existing Loan Documents.

 

5.
RATIFICATION OF PERFECTION CERTIFICATES.

 

	 	A.	Parent hereby ratifies, confirms and reaffirms, all
and singular, the terms and disclosures contained in a certain Perfection Certificate of Parent dated as of December 26, 2019,
and acknowledges, confirms and agrees the disclosures and information Parent provided to Bank in such Perfection Certificate have
not changed, as of the date hereof.

 

    	 	1	 

    	 

    

 

	 	B.	Misonix hereby ratifies, confirms and reaffirms, all
and singular, the terms and disclosures contained in a certain Perfection Certificate of Misonix dated as of December 26, 2019,
and acknowledges, confirms and agrees the disclosures and information Misonix provided to Bank in such Perfection Certificate
have not changed, as of the date hereof.
	 	 	 
	 	C.	Solsys hereby ratifies, confirms and reaffirms, all
and singular, the terms and disclosures contained in a certain Perfection Certificate of Solsys dated as of December 26, 2019,
and acknowledges, confirms and agrees the disclosures and information Solsys provided to Bank in such Perfection Certificate have
not changed, as of the date hereof.

 

6.
RATIFICATION OF INTELLECTUAL PROPERTY SECURITY AGREEMENTS.

 

	 	A.	Parent hereby ratifies, confirms and reaffirms, all
and singular, the terms and conditions of the Parent Intellectual Property Security Agreement, and acknowledges, confirms and
agrees that the Parent Intellectual Property Security Agreement contains an accurate and complete listing of all Intellectual
Property Collateral as defined in said Parent Intellectual Property Security Agreement, and shall remain in full force and effect.
	 	 	 
	 	B.	Misonix hereby ratifies, confirms and reaffirms, all
and singular, the terms and conditions of the Misonix Intellectual Property Security Agreement, and acknowledges, confirms and
agrees that the Misonix Intellectual Property Security Agreement contains an accurate and complete listing of all Intellectual
Property Collateral as defined in said Misonix Intellectual Property Security Agreement, and shall remain in full force and effect.
	 	 	 
	 	C.	Solsys hereby ratifies, confirms and reaffirms, all
and singular, the terms and conditions of the Solsys Intellectual Property Security Agreement, and acknowledges, confirms and
agrees that the Solsys Intellectual Property Security Agreement contains an accurate and complete listing of all Intellectual
Property Collateral as defined in said Solsys Intellectual Property Security Agreement, and shall remain in full force and effect.

 

7.
CONSISTENT CHANGES. The Existing Loan Documents are hereby amended wherever necessary to reflect the changes described
above.

 

8.
RATIFICATION OF LOAN DOCUMENTS. Borrower hereby ratifies, confirms, and reaffirms all terms and conditions of all security
or other collateral granted to Bank, and confirms that the indebtedness secured thereby includes, without limitation, the Obligations.

 

9.
Intentionally omitted.

 

10.
CONTINUING VALIDITY. Borrower understands and agrees that in modifying the existing Obligations, Bank is relying upon Borrower’s
representations, warranties, and agreements, as set forth in the Existing Loan Documents. Except as expressly modified pursuant
to this Loan Modification Agreement, the terms of the Existing Loan Documents remain unchanged and in full force and effect. Bank’s
agreement to modifications to the existing Obligations pursuant to this Loan Modification Agreement in no way shall obligate Bank
to make any future modifications to the Obligations. Nothing in this Loan Modification Agreement shall constitute a satisfaction
of the Obligations. It is the intention of Bank and Borrower to retain as liable parties all makers of Existing Loan Documents,
unless the party is expressly released by Bank in writing. No maker will be released by virtue of this Loan Modification Agreement.

 

11.
COUNTERSIGNATURE. This Loan Modification Agreement shall become effective only when it shall have been executed by Borrower
and Bank.

 

[The
remainder of this page is intentionally left blank]

 

    	 	2	 

    	 

    

 

This
Loan Modification Agreement is executed as a sealed instrument under the laws of the Commonwealth of Massachusetts as of the date
first written above.

 

	BORROWER:	 
	 	 	 
	MISONIX,
    INC.	 
	 	 	 
	By	/s/
    Joseph P. Dwyer	 
	Name:	Joseph
    P. Dwyer	 
	Title:	Chief
    Financial Officer	 
	 	 	 
	MISONIX
    OPCO, INC.	 
	 	 	 
	By	/s/
    Joseph P. Dwyer	 
	Name:	Joseph
    P. Dwyer	 
	Title:	Chief
    Financial Officer	 
	 	 	 
	SOLSYS
    MEDICAL, LLC	 
	 	 	 
	By	/s/
    Joseph P. Dwyer	 
	Name:	Joseph
    P. Dwyer	 
	Title:	Chief
    Financial Officer	 
	 	 	 
	BANK:	 
	 	 	 
	SILICON
    VALLEY BANK	 
	 	 	 
	By	/s/
    Sam Subilia	 
	Name:	Sam
    Subilia	 
	Title:	DirectorExhibit 10.1

 

OPEN MARKET SALE AGREEMENTSM

 

September 3, 2020

 

JEFFERIES LLC

520 Madison Avenue

New York, New York 10022

 

Ladies and Gentlemen:

 

Cyclerion Therapeutics, Inc.,
a Massachusetts corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to
issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares
of the Company’s common stock, no par value per share (the “Common Shares”), on the terms set forth in
this agreement (this “Agreement”).

 

Section 1.         DEFINITIONS

 

(a)            Certain
Definitions. For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall have the following
respective meanings:

 

“Affiliate”
of a Person means another Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or
is under common control with, such first- mentioned Person. The term “control” (including the terms “controlling,”
“controlled by” and “under common control with”) means the possession, direct or indirect, of the power
to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities,
by contract or otherwise.

 

“Agency Period”
means the period commencing on the date of this Agreement and expiring on the earliest to occur of (x) the date on which the
Agent shall have placed the Maximum Program Amount pursuant to this Agreement and (y) the date this Agreement is terminated
pursuant to ‎Section 7.

 

“Commission”
means the U.S. Securities and Exchange Commission.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.

 

“Floor Price”
means the minimum price set by the Company in the Issuance Notice below which the Agent shall not sell Shares during the applicable
period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth in the Issuance
Notice by delivering written notice of such change to the Agent and which in no event shall be less than $1.00 without the prior
written consent of the Agent, which may be withheld in the Agent’s sole discretion.

 

 

SM “Open Market Sale Agreement” is a
service mark of Jefferies LLC

 

     

     

    

 

“Issuance
Amount” means the aggregate Sales Price of the Shares to be sold by the Agent pursuant to any Issuance Notice.

 

“Issuance
Notice” means a written notice delivered to the Agent by the Company in accordance with this Agreement in the form attached
hereto as Exhibit A that is executed by its Chief Executive Officer, President or Chief Financial Officer.

 

“Issuance
Notice Date” means any Trading Day during the Agency Period that an Issuance Notice is delivered pursuant to ‎Section 3(b)(i).

 

“Issuance
Price” means the Sales Price less the Selling Commission.

 

“Maximum Program
Amount” means Common Shares with an aggregate Sales Price of the lesser of (a) the number or dollar amount of Common
Shares registered under the effective Registration Statement (defined below) pursuant to which the offering is being made, (b) the
number of authorized but unissued Common Shares (less Common Shares issuable upon exercise, conversion or exchange of any outstanding
securities of the Company or otherwise reserved from the Company’s authorized capital stock), (c) the number or dollar
amount of Common Shares permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable),
or (d) the number or dollar amount of Common Shares for which the Company has filed a Prospectus (defined below).

 

“Person”
means an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated association,
joint venture, joint stock company, governmental authority or other entity of any kind.

 

“Principal
Market” means the Nasdaq Global Select Market or such other national securities exchange on which the Common Shares,
including any Shares, are then listed.

 

“Sales Price”
means the actual sale execution price of each Share placed by the Agent pursuant to this Agreement.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.

 

“Selling Commission”
means three percent (3.0%) of the gross proceeds of Shares sold pursuant to this Agreement, or as otherwise agreed between the
Company and the Agent with respect to any Shares sold pursuant to this Agreement.

 

“Settlement
Date” means the second business day following each Trading Day during the period set forth in the Issuance Notice on
which Shares are sold pursuant to this Agreement, when the Company shall deliver to the Agent the amount of Shares sold on such
Trading Day and the Agent shall deliver to the Company the Issuance Price received on such sales.

 

    2

     

    

 

“Shares”
shall mean the Company’s Common Shares issued or issuable pursuant to this Agreement.

 

“Trading Day”
means any day on which the Principal Market is open for trading.

 

Section 2.         REPRESENTATIONS
AND WARRANTIES OF THE COMPANY

 

The Company represents
and warrants to, and agrees with, the Agent that as of (1) the date of this Agreement, (2) each Issuance Notice Date,
(3) each Settlement Date, (4) each Triggering Event Date and (5) as of each Time of Sale (each of the times referenced
above is referred to herein as a “Representation Date”), except as may be disclosed in the Prospectus (including
any documents incorporated by reference therein and any supplements thereto) on or before a Representation Date:

 

(a)            Registration
Statement. The Company has prepared and filed with the Commission a shelf registration statement on Form S-3 (File No. 333-240095)
that contains a base prospectus (the “Base Prospectus”). Such registration statement registers the issuance
and sale by the Company of the Shares under the Securities Act. The Company may file one or more additional registration statements
from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable, with respect
to the Shares. Except where the context otherwise requires, such registration statement(s), including any information deemed to
be a part thereof pursuant to Rule 430B under the Securities Act, including all financial statements, exhibits and schedules
thereto and all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3 under
the Securities Act as from time to time amended or supplemented, is herein referred to as the “Registration Statement,”
and the prospectus constituting a part of such registration statement(s), together with any prospectus supplement filed with the
Commission pursuant to Rule 424(b) under the Securities Act relating to a particular issuance of the Shares, including
all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3 under the Securities
Act, in each case, as from time to time amended or supplemented, is referred to herein as the “Prospectus,”
except that if any revised prospectus is provided to the Agent by the Company for use in connection with the offering of the Shares
that is not required to be filed by the Company pursuant to Rule 424(b) under the Securities Act, the term “Prospectus”
shall refer to such revised prospectus from and after the time it is first provided to the Agent for such use. The Registration
Statement at the time it originally became effective is herein called the “Original Registration Statement.”
As used in this Agreement, the terms “amendment” or “supplement” when applied to the Registration Statement
or the Prospectus shall be deemed to include the filing by the Company with the Commission of any document under the Exchange Act
after the date hereof that is or is deemed to be incorporated therein by reference.

 

All references in this
Agreement to financial statements and schedules and other information which is “contained,” “included”
or “stated” in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed
to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated
by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus,
as the case may be, as of any specified date; and all references in this Agreement to amendments or supplements to the Registration
Statement or the Prospectus shall be deemed to mean and include, without limitation, the filing of any document under the Exchange
Act which is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included
in the Registration Statement or the Prospectus, as the case may be, as of any specified date. The Company’s obligations
under this Agreement to furnish, provide, deliver or make available (and all other references of like import) copies of any report
or statement shall be deemed satisfied if the same is filed with the Commission through its Electronic Data Gathering, Analysis
and Retrieval system (“EDGAR”).

 

    3

     

    

 

At the time the Original
Registration Statement was or will be declared effective and at the time the Company’s most recent annual report on Form 10-K
was filed with the Commission, if later, the Company met the then-applicable requirements for use of Form S-3 under the Securities
Act. During the Agency Period, each time the Company files an annual report on Form 10-K the Company will meet the then-applicable
requirements for use of Form S-3 under the Securities Act.

 

(b)            Compliance
with Registration Requirements. The Original Registration Statement and any Rule 462(b) Registration Statement have
been declared effective by the Commission under the Securities Act. The Company has complied to the Commission’s satisfaction
with all requests of the Commission for additional or supplemental information. No stop order suspending the effectiveness of the
Registration Statement or any Rule 462(b) Registration Statement is in effect and no proceedings for such purpose have
been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by the Commission.

 

The Prospectus when
filed complied or will comply in all material respects with the Securities Act and, if filed with the Commission through EDGAR
(except as may be permitted by Regulation S-T under the Securities Act), was identical to the copy thereof delivered to the Agent
for use in connection with the issuance and sale of the Shares. Each of the Registration Statement, any Rule 462(b) Registration
Statement and any post-effective amendment thereto, at the time it became or becomes effective and at each Representation Date,
complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not
misleading. As of the date of this Agreement, the Prospectus and any Free Writing Prospectus (as defined below) considered together
(collectively, the “Time of Sale Information”) did not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made,
not misleading. The Prospectus, as amended or supplemented, as of its date and at each Representation Date, did not and will not
contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the
three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, any Rule 462(b) Registration
Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance
upon and in conformity with information relating to the Agent furnished to the Company in writing by the Agent expressly for use
therein, it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information
described in Section 6 below. There are no contracts or other documents required to be described in the Prospectus
or to be filed as exhibits to the Registration Statement which have not been described or filed as required. The Registration Statement
and the offer and sale of the Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and
comply in all material respects with said rule.

 

    4

     

    

 

(c)            Ineligible
Issuer Status. The Company is not an “ineligible issuer” in connection with the offering of the Shares pursuant
to Rules 164, 405 and 433 under the Securities Act. Any Free Writing Prospectus that the Company is required to file pursuant
to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements
of the Securities Act. Each Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under
the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all
material respects with the requirements of Rule 433 under the Securities Act including timely filing with the Commission or
retention where required and legending, and each such Free Writing Prospectus, as of its issue date and at all subsequent times
through the completion of the issuance and sale of the Shares did not, does not and will not include any information that conflicted,
conflicts with or will conflict with the information contained in the Registration Statement or the Prospectus, including any document
incorporated by reference therein. Except for the Free Writing Prospectuses, if any, and electronic road shows, if any, furnished
to the Agent before first use, the Company has not prepared, used or referred to, and will not, without the Agent’s prior
consent, prepare, use or refer to, any Free Writing Prospectus, any such consent not to be unreasonably withheld, conditioned or
delayed.

 

(d)            Incorporated
Documents. The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the Prospectus,
at the time they were filed with the Commission, complied in all material respects with the requirements of the Exchange Act, as
applicable, and, when read together with the other information in the Prospectus, do not contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading.

 

(e)            Exchange
Act Compliance. The documents incorporated or deemed to be incorporated by reference in the Prospectus, at the time they were
or hereafter are filed with the Commission, and any Free Writing Prospectus or amendment or supplement thereto complied and will
comply in all material respects with the requirements of the Exchange Act, and, when read together with the other information in
the Prospectus, at the time the Registration Statement and any amendments thereto become effective and at each Time of Sale (as
defined below), as the case may be, will not contain an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the fact required to be stated therein or necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading.

 

(f)            Statistical
and Market-Related Data. All statistical, demographic and market-related data included in the Registration Statement or the
Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate.
To the extent required, the Company has obtained the written consent for the use of such data from such sources.

 

    5

     

    

 

(g)            Disclosure
Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting. The Company has established
and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are
designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to
the Company’s principal executive officer and its principal financial officer by others within those entities, particularly
during the periods in which the periodic reports required under the Exchange Act are being prepared (it being understood that neither
subsection (m) nor this subsection requires the Company to comply with Section 404 of the Sarbanes-Oxley Act of 2002
as of an earlier date than it would otherwise be required to so comply under applicable law); (ii) have been evaluated by
management of the Company for effectiveness as of the end of the Company’s most recent fiscal quarter; and (iii) are
effective in all material respects to perform the functions for which they were established. Since the end of the Company’s
most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company’s internal
control over financial reporting (whether or not remediated) and no change in the Company’s internal control over financial
reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over
financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred
during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s
internal control over financial reporting.

 

(h)            This
Agreement. This Agreement has been duly authorized, executed and delivered by the Company.

 

(i)             Authorization
of the Shares. The Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered
by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the
issuance and sale of the Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe
for or purchase the Shares.

 

(j)             No
Applicable Registration or Other Similar Rights. There are no persons with registration or other similar rights to have any
equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this
Agreement, except for such rights as have been duly waived.

 

(k)            No
Material Adverse Change. Except as otherwise disclosed in the Registration Statement and the Prospectus, subsequent to
the respective dates as of which information is given in the Registration Statement and the Prospectus: (i) there has
been no material adverse change, or any development that would reasonably be expected to result in a material adverse change,
in (A) the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results,
assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company
and its subsidiaries, considered as one entity, or (B) the ability of the Company to consummate the transactions contemplated
by this Agreement or perform its obligations hereunder (any such change being referred to herein as a “Material
Adverse Change”); (ii) the Company and its subsidiaries, considered as one entity, have not incurred any
material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference
with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by
insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material,
individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into
any transactions not in the ordinary course of business; and (iii) there has not been any material decrease in the
capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries and
there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to
the Company or other subsidiaries, by any of the Company’s subsidiaries on any class of capital stock, or any
repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock.

 

    6

     

    

 

(l)             Independent
Accountants. Ernst & Young LLP, which has expressed its opinion with respect to the financial statements (which term
as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement
and the Prospectus, is (i) an independent registered public accounting firm as required by the Securities Act , the Exchange
Act, and the rules of the Public Company Accounting Oversight Board (“PCAOB”), (ii) in compliance
with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the
Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended
or revoked and who has not requested such registration to be withdrawn.

 

(m)           Financial
Statements. The financial statements filed with the Commission as a part of the Registration Statement and the Prospectus present
fairly in all material respects the consolidated financial position of the Company and its subsidiaries as of the dates indicated
and the results of their operations, changes in stockholders’ equity and cash flows for the periods specified. Such financial
statements have been prepared in conformity with United States generally accepted accounting principles (“U.S. GAAP”)
applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto and
except in the case of unaudited financial statements, which are subject to normal and recurring year-end adjustments and do not
contain all footnotes or contain limited footnotes. The interactive data in eXtensible Business Reporting Language included or
incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and
has been prepared in accordance with the Commission’s rules and guidelines applicable thereto. No other financial statements
or supporting schedules are required to be included in the Registration Statement or the Prospectus. The financial data set forth
in or incorporated by reference into each of the Registration Statement and the Prospectus fairly present, in all material respects,
the information set forth therein on a basis consistent with that of the audited financial statements contained in or incorporated
by reference into the Registration Statement and the Prospectus. To the Company’s knowledge, no person who has been suspended
or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant
to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial
statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement and
the Prospectus.

 

(n)            Company’s
Accounting System. The Company and each of its subsidiaries make and keep books and records that are accurate in all material
respects and maintain a system of internal accounting controls designed to provide
reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorization;
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with U.S. GAAP and
to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general
or specific authorization; (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals
and appropriate action is taken with respect to any differences; and (v) the interactive data in eXtensible Business Reporting
Language included or incorporated by reference in the Registration Statement and the Prospectus fairly presents the information
called for in all material respects and is prepared in accordance with the Commission's rules and guidelines applicable thereto.

 

    7

     

    

 

(o)            Incorporation
and Good Standing of the Company. The Company has been duly incorporated and is validly existing as a corporation in good standing
under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its
properties and to conduct its business as described in the Registration Statement and the Prospectus and to enter into and perform
its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good
standing in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property
or the conduct of business, except where the failure to be so qualified or in good standing or to have such power or authority
would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change.

 

(p)            Subsidiaries.
Each of the Company’s “subsidiaries” (for purposes of this Agreement, as defined in Rule 405 under the
Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation,
partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its
incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties
and to conduct its business as described in the Registration Statement and the Prospectus. Each of the Company’s
subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact
business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the
ownership or leasing of property or the conduct of business, except where the failure to be so qualified or in good standing,
as the case may be, or to have such power or authority would not reasonably be expected, individually or in the aggregate, to
result in a Material Adverse Change.. All of the issued and outstanding capital stock or other equity or ownership interests
of each of the Company’s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable
and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge,
lien, encumbrance or adverse claim. None of the outstanding capital stock or equity interest in any subsidiary was
issued in violation of preemptive or similar rights of any security holder of such subsidiary. The constitutive or
organizational documents of each of the subsidiaries comply in all material respects with the requirements of applicable laws
of its jurisdiction of incorporation or organization and are in full force and effect. The Company does not own or control,
directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21 to
the Company’s most recent Annual Report on Form 10-K.

 

(q)            Capitalization
and Other Capital Stock Matters. The authorized, issued and outstanding capital stock of the Company is as set forth in the
Registration Statement and the Prospectus under the caption “Capitalization” (other than for subsequent issuances,
if any, pursuant to employee benefit plans or upon the exercise of outstanding options or warrants, in each case described in the
Registration Statement and the Prospectus). The Common Shares (including the Shares) conform in all material respects to the description
thereof contained in the Prospectus. All of the issued and outstanding Common Shares have been duly authorized and validly issued,
are fully paid and nonassessable and have been issued in compliance with all applicable federal and state securities laws. None
of the outstanding Common Shares was issued in violation of any preemptive rights, rights of first refusal or other similar rights
to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights,
rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable
for, any capital stock of the Company or any of its subsidiaries other than those described in the Registration Statement and the
Prospectus. The descriptions of the Company’s stock option, stock bonus and other stock plans or arrangements, and the options
or other rights granted thereunder, set forth in the Registration Statement and the Prospectus accurately and fairly presents in
all material respects the information required to be shown with respect to such plans, arrangements, options and rights.

 

    8

     

    

 

(r)             Stock
Exchange Listing. The Common Shares are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and
are listed on the Principal Market, and the Company has taken no action designed to, or likely to have the effect of, terminating
the registration of the Common Shares under the Exchange Act or delisting the Common Shares from the Principal Market, nor has
the Company received any notification that the Commission or the Principal Market is contemplating terminating such registration
or listing. To the Company’s knowledge, it is in compliance with all applicable listing requirements of the Principal Market.

 

(s)            Non-Contravention
of Existing Instruments; No Further Authorizations or Approvals Required. Neither the Company nor any of its subsidiaries is
in violation of its charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable,
or is in default (or, with the giving of notice or lapse of time, would be in default) (“Default”) under any
indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without
limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing
or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound,
or to which any of their respective properties or assets are subject (each, an “Existing Instrument”), except
for such Defaults as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change.
The Company’s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby
and by the Registration Statement and the Prospectus and the issuance and sale of the Shares (including the use of proceeds from
the sale of the Shares as described in the Registration Statement and the Prospectus under the caption “Use of Proceeds”)
(i) have been duly authorized by all necessary corporate action and will not result in any violation of the provisions of
the charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the
Company or any subsidiary (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering
Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or
assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument,
and (iii) will not result in any violation of any law, administrative regulation or administrative or court decree applicable
to the Company or any of its subsidiaries, except in the case of clauses (ii) or (iii) above, as would not reasonably
be expected, individually or in the aggregate, to result in a Material Adverse Change. No consent, approval, authorization or other
order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the
Company’s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby
and by the Registration Statement and the Prospectus, except such as have been obtained or made by the Company and are in full
force and effect under the Securities Act and such as may be required under applicable state securities or blue sky laws or FINRA
(as defined below). As used herein, a “Debt Repayment Triggering Event” means any event or condition which gives,
or with the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or
any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion
of such indebtedness by the Company or any of its subsidiaries.

 

    9

     

    

 

(t)             No
Material Actions or Proceedings. Except as otherwise disclosed in the Prospectus, there is no action, suit, proceeding,
inquiry or investigation brought by or before any legal or governmental entity now pending or, to the knowledge of the
Company, threatened, against or affecting the Company or any of its subsidiaries, which would reasonably be expected,
individually or in the aggregate, to result in a Material Adverse Change; and the aggregate of all pending legal or
governmental proceedings to which the Company or any such subsidiary is a party or of which any of their respective
properties or assets is the subject, including ordinary routine litigation incidental to the business, if determined
adversely to the Company, would not reasonably be expected to result in a Material Adverse Change. No material labor dispute
with the employees of the Company or any of its subsidiaries exist or, to the knowledge of the Company, is threatened or
imminent. To the knowledge of the Company, no material labor disputes with the employees of any principal supplier,
manufacturer, customer or contractor of the Company exists or is threatened.

 

(u)            Intellectual
Property Rights. Except as otherwise disclosed in the Registration Statement or the Prospectus, the Company and its subsidiaries
own, or have obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names,
service names, copyrights, trade secrets and other intellectual property described in the Registration Statement and the Prospectus
as being owned or licensed by them or which are material to and necessary for the conduct of their respective businesses as currently
conducted or as currently proposed to be conducted (collectively, “Intellectual Property”) and, to the Company’s
knowledge, the conduct of their respective businesses currently does not and will not, upon the commercialization of any product
or service  currently proposed, infringe in any material respect  any intellectual property rights of others.
The Intellectual Property of the Company has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable,
in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. To
the Company’s knowledge: (i) there are no third parties who have rights to any Intellectual Property, except for customary
reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement
and the Prospectus as licensed to the Company or one or more of its subsidiaries; and (ii) there is no infringement by third
parties of any Intellectual Property. There is no pending or, to the Company’s knowledge, threatened action, suit, proceeding
or claim by others: (A) challenging the Company’s rights in or to any Intellectual Property, and the Company is unaware
of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B) challenging the validity,
enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis
for any such action, suit, proceeding or claim; or (C) asserting that the Company or any of its subsidiaries infringes or
otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement or the
Prospectus as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret
or other proprietary rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such
action, suit, proceeding or claim. The Company and its subsidiaries have complied in all material respects with the terms of each
agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are
in full force and effect. To the Company’s knowledge, there are no material defects of form or procedural defects in any
of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken all reasonable
steps to protect, maintain and safeguard their Intellectual Property, including the execution of appropriate nondisclosure, confidentiality
agreements and invention assignment agreements and invention assignments with their employees, and, to the knowledge of the Company,
no employee of the Company is in or has been in violation in any material respect of any term of any employment contract, patent
disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement,
or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee’s employment
with the Company. The duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution
of the United States patents and patent applications included in the Intellectual Property have been complied with; and in all
foreign offices having similar requirements, all such requirements have been complied with. None of the
Company owned Intellectual Property or technology (including information technology and outsourced arrangements) employed by the
Company or its subsidiaries has been obtained or is being used by the Company or its subsidiary in violation of any contractual
obligation binding on the Company or its subsidiaries or any of their respective officers, directors or employees or otherwise
in violation of the rights of any persons in any material respect. The product candidates described in the Registration Statement
and the Prospectus as under development by the Company or any subsidiary fall within the scope of the claims of one or more patents
or patent applications owned by, or exclusively licensed to, the Company or any subsidiary.

 

    10

     

    

 

(v)            All
Necessary Permits, etc. Except as otherwise disclosed in the Prospectus, the Company and each subsidiary possess such
valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to
conduct their respective businesses as currently conducted and as described in the Registration Statement or the Prospectus (“Permits”),
except where the failure to possess the same or so qualify would not reasonably be expected, individually or in the aggregate,
to result in a Material Adverse Change. Neither the Company nor any of its subsidiaries is in violation of, or in default under,
any of the Permits or has received any notice of proceedings relating to the revocation or modification of, or non compliance with,
the Permits, except for such violations, defaults or proceedings which, if resolved unfavorably, would not reasonably be expected,
individually or in the aggregate, to result in a Material Adverse Change.

 

(w)            Title
to Properties. Except as otherwise disclosed in the Prospectus, the Company and its subsidiaries have good and marketable title
to all of the real and personal property and other assets reflected as owned in the financial statements referred to in ‎Section 2(m) above
(or elsewhere in the Registration Statement or the Prospectus, in each case free and clear of any security interests, mortgages,
liens, encumbrances, equities, adverse claims and other defects, except as would not reasonably be expected, individually or in
the aggregate, to materially affect the value of such property or materially interfere with the use thereof. The real property,
improvements, equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and
enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be
made of such real property, improvements, equipment or personal property by the Company or such subsidiary.

 

    11

     

    

 

(x)             Tax
Law Compliance. Except in any case in which failure to pay or file (as applicable) would not, individually or in the aggregate,
result in a Material Adverse Change, the Company and its subsidiaries have filed all necessary federal, state and foreign income
and franchise tax returns or have properly requested extensions thereof and have paid all taxes required to be paid by any of them
and, if due and payable, any related or similar assessment, fine or penalty levied against any of them except as may be being contested
in good faith and by appropriate proceedings. Except to the extent of any inadequacy that would not, individually or in the aggregate,
result in a Material Adverse Change, the Company has made adequate charges, accruals and reserves in the applicable financial statements
referred to in ‎Section 2(m) above in respect of all federal, state and foreign income and franchise taxes
for all periods as to which the tax liability of the Company or any of its subsidiaries has not been finally determined.

 

(y)            Company
Not an “Investment Company.” The Company is not, and will not be, either after receipt of payment for the Shares
or after the application of the proceeds therefrom as described under “Use of Proceeds” in the Registration Statement
or the Prospectus, required to register as an “investment company” under the Investment Company Act of 1940, as amended
(the “Investment Company Act”).

 

(z)             Insurance.
Except as otherwise disclosed in the Prospectus, each of the Company and its subsidiaries are insured by recognized, financially
sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally
deemed adequate and customary, in the reasonable judgment of the Company’s Board of Directors, for their businesses including,
but not limited to, policies covering real and personal property owned or leased by the Company and its subsidiaries against theft,
damage, destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product liability
claims and clinical trial liability claims. The Company has no reason to believe that it or any of its subsidiaries will not be
able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage
from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would
not reasonably be expected to result in a Material Adverse Change. Neither the Company nor any of its subsidiaries has been denied
any insurance coverage which it has sought or for which it has applied.

 

(aa)          No
Price Stabilization or Manipulation; Compliance with Regulation M. Neither the Company nor any of its subsidiaries has
taken, directly or indirectly (without giving effect to the activities of the Agent other than sales of Shares pursuant to
and in accordance with this Agreement), any action designed to or that would reasonably be expected to cause or result in
stabilization or manipulation of the price of the Common Shares or of any “reference security” (as defined in
Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Common Shares,
whether to facilitate the sale or resale of the Shares or otherwise, and has taken no action which would directly or
indirectly violate Regulation M.

 

(bb)         Related
Party Transactions. There are no business relationships or related-party transactions involving the Company or any of its subsidiaries
or any other person required to be described in the Registration Statement or the Prospectus which have not been described as required.

 

    12

     

    

 

(cc)          FINRA
Matters. All of the information provided to the Agent or to counsel for the Agent by the Company, and to the knowledge of
the Company, its counsel, its officers and directors and the holders of any securities (debt or equity) or options to acquire
any securities of the Company in connection with the offering of the Shares is true, complete, correct and compliant with Financial
Industry Regulatory Authority, Inc.’s (“FINRA”) rules and any letters, filings or other supplemental
information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct.

 

(dd)         No
Unlawful Contributions or Other Payments. Except as otherwise disclosed in the Prospectus, neither the Company nor any of
its subsidiaries nor, to the Company’s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution
or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any applicable law
or of the character required to be disclosed in the Registration Statement and the Prospectus.

 

(ee)          Compliance
with Environmental Laws. Except as described in the Prospectus and except as would not reasonably be expected, individually
or in the aggregate, to result in a Material Adverse Change; (i) neither the Company nor any of its subsidiaries is in violation
of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any
judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment,
relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water,
groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the
release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum
or petroleum products (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution,
use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”),
(ii) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental
Laws and are each in compliance with their requirements, (iii) there are no pending or, to the knowledge of the Company, threatened
administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation,
investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries and (iv) there
are no orders for clean-up or remediation, or any actions, suits or proceedings by any private party or governmental body or agency,
against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws.

 

(ff)           ERISA
Compliance. Except as otherwise disclosed in the Prospectus, the Company and its subsidiaries and any “employee benefit
plan” (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published
interpretations thereunder (collectively, “ERISA”)) established or maintained by the Company, its subsidiaries
or their “ERISA Affiliates” (as defined below) (the “Plans”) are in compliance with ERISA, except
as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. “ERISA
Affiliate” means, with respect to the Company or any of its subsidiaries, any member of any group of organizations described
in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published
interpretations thereunder (the “Code”) of which the Company or such subsidiary is a member. No “employee benefit plan” established or maintained
by the Company, its subsidiaries or any of their ERISA Affiliates, if such “employee benefit plan” were terminated,
would have any “amount of unfunded benefit liabilities” (as defined under ERISA).  Neither the Company, its subsidiaries
nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i) Title IV of ERISA with respect
to termination of, or withdrawal from, any “employee benefit plan” or (ii) Sections 412, 4971, 4975 or 4980B of the
Code. Neither the Company,
its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i) Title
IV of ERISA with respect to termination of, or withdrawal from, any Plan or (ii) except as would not reasonably be expected,
individually or in the aggregate, to result in a Material Adverse Change with respect to Sections 412, 4971, 4975 or 4980B of the
Code. Each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred,
whether by action or failure to act, which would reasonably be expected to cause the loss of such qualification.

 

    13

     

    

 

(gg)          Brokers.
Except as otherwise disclosed in the Prospectus, there is no broker, finder or other party that is entitled to receive from the
Company any brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this Agreement.

 

(hh)         No
Outstanding Loans or Other Extensions of Credit. The Company does not have any outstanding extension of credit, in the form
of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions
of credit as are expressly permitted by Section 13(k) of the Exchange Act.

 

(ii)            Compliance
with Laws. The Company and its subsidiaries have been and are in compliance with all applicable laws, rules and regulations,
except where failure to be so in compliance would not reasonably be expected, individually or in the aggregate, to result in a
Material Adverse Change.

 

(jj)            Dividend
Restrictions. Except as disclosed in the Prospectus, no subsidiary of the Company is prohibited or restricted, directly or
indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiary’s
equity securities or from repaying to the Company or any other subsidiary of the Company any amounts that may from time to time
become due under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company
or to any other subsidiary except, in each case, for such restrictions or prohibitions imposed under applicable law.

 

(kk)          Anti-Corruption
and Anti-Bribery Laws. Neither the Company nor any of its subsidiaries nor any director, officer, or employee of the
Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on
behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any
of its subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful
expenses relating to political activity; (ii) made or taken any act in furtherance of an offer, promise, or
authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or
employee, including of any government-owned or controlled entity or public international organization, or any political
party, party official, or candidate for political office; (iii) violated or is in violation of any provision of the U.S.
Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), the UK Bribery Act 2010, or any other
applicable anti-bribery or anti-corruption law; or (iv) made, offered, authorized, requested, or taken an act in
furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The
Company and its subsidiaries and, to the knowledge of the Company, the Company’s affiliates have conducted their
respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to
ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.

 

    14

     

    

 

(ll)            Money
Laundering Laws. The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related
or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively,
the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws
is pending or, to the knowledge of the Company, threatened.

 

(mm)        Clinical
Data and Regulatory Compliance. The preclinical tests and clinical trials, and other studies (collectively, “studies”)
that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still
pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved
for such studies and with standard medical and scientific research procedures; each description of the results of such studies
is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and
its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question,
the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made
all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department
of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory
agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither
the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the
termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement
or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects
with all applicable rules, regulations and policies of the Regulatory Agencies.

 

(nn)         Sanctions.
Neither the Company nor any of its subsidiaries, directors or officers, nor, to the knowledge of the Company, after due
inquiry, any employee, agent, or other person acting on behalf of the Company or any of its subsidiaries is currently the
subject or the target of any applicable sanctions, including but not limited to those administered by the Office of Foreign
Assets Control of the U.S. Department of the Treasury (“OFAC”) (collectively,
“Sanctions”); nor is the Company or any of its subsidiaries located, organized or resident in a country or
territory that is the subject or target of any Sanctions, including, without limitation, Crimea, Cuba, Iran, North
Korea, and Syria (collectively, “Sanctioned Countries”); and the Company will not directly or indirectly
use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any
joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person,
or in any country or territory, that at the time of such financing, is the subject or target of any Sanctions  or in any other manner that will result in a violation by any person (including any person participating in the
transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years, the
Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions
with any person that at the time of the dealing or transaction is or was the subject of Sanctions or with any Sanctioned
Country.

 

    15

     

    

 

(oo)         Sarbanes-Oxley.
There is and has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities
as such, to comply with any provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated
in connection therewith (the “Sarbanes-Oxley Act”), with which the Company is required to comply, including Section 402
related to loans.

 

(pp)         Duties,
Transfer Taxes, Etc. No stamp or other issuance or transfer taxes or duties and no capital gains, income, withholding or other
taxes are payable by the Agent in the United States or any political subdivision or taxing authority thereof or therein in connection
with the execution, delivery or performance of this Agreement by the Company or the sale and delivery by the Company of the Shares.

 

(qq)         Cybersecurity.
The Company’s and its subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware,
software, websites, applications, and databases (collectively, “IT Systems”) are adequate for, and operate and
perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries
as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants.
The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative
controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity,
continuous operation, redundancy and security of all IT Systems and data, including “Personal Data,” used in connection
with their businesses. “Personal Data” means (i) a natural person’s name, street address, telephone
number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport
number, credit card number, bank information, or customer or account number; (ii) any information which would qualify as “personally
identifying information” under the Federal Trade Commission Act, as amended; (iii) “personal data” as defined
by GDPR (as defined below); (iv) any information which would qualify as “protected health information” under the
Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical
Health Act (collectively, “HIPAA”); and (v) any other piece of information that allows the identification
of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person’s
health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or accesses to same, except
for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents
under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance
with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental
or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal
Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.

 

(rr)           Compliance
with Data Privacy Laws. The Company and its subsidiaries are, and at all prior times were, in material compliance with all
applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company
and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been
and currently are in material compliance with, the European Union General Data Protection Regulation (“GDPR”)
(EU 2016/679) (collectively, the “Privacy Laws”). To ensure compliance with the Privacy Laws, the Company and
its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material
respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure,
handling, and analysis of Personal Data (the “Policies”). The Company and its subsidiaries have at all times
made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such
disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable
laws and regulatory rules or requirements in any material respect. The Company further certifies that neither it nor any subsidiary:
(i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any
of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice;
(ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action
pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability
under any Privacy Law.

 

    16

     

    

 

(ss)          Other
Underwriting Agreements. The Company is not a party to any agreement with an agent or underwriter for any other “at the
market” or continuous equity transaction.

 

(tt)           Compliance
with Health Care Laws. The Company and its subsidiaries are, and at all times have been, in material compliance with all
applicable Health Care Laws. For purposes of this Agreement, “Health Care Laws” means: (i) the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.), the Public Health Service Act (42 U.S.C.
Section 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable federal, state, local and
foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C.
Section 1320a-7b(b)), the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal false statements
law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under
HIPAA (42 U.S.C. Section 1320d et seq.), the Stark Law (42 U.S.C. Section 1395nn), the civil monetary penalties law
(42 U.S.C. Section 1320a-7a), the exclusion law (42 U.S.C. Section 1320a-7), the Physician Payments Sunshine Act
(42 U.S.C. Section 1320-7h), and applicable laws governing government funded or sponsored healthcare programs;
(iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C.
Section 17921 et seq.) and comparable state health care data privacy and security laws; (iv) the Patient Protection
and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; and
(v) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or
regulatory bodies. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit,
proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or
regulatory authority or third party alleging that any product operation or activity is in material violation of any Health
Care Laws nor, to the Company’s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action threatened. The Company and its subsidiaries have filed, maintained or submitted
all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as
required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or
supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate
integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any
governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor any of their respective
employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal
health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry,
investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or
exclusion.

 

    17

     

    

 

Any certificate signed
by any officer or representative of the Company or any of its subsidiaries and delivered to the Agent or counsel for the Agent
in connection with an issuance of Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters
covered thereby on the date of such certificate.

 

The Company acknowledges
that the Agent and, for purposes of the opinions to be delivered pursuant to Section 4(o) hereof, counsel to the
Company and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents
to such reliance.

 

Section 3.          ISSUANCE
AND SALE OF COMMON SHARES

 

(a)            Sale
of Securities. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and
conditions herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell Shares through
the Agent, acting as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales Price of up
to the Maximum Program Amount, based on and in accordance with Issuance Notices as the Company may deliver, during the Agency Period.

 

(b)            Mechanics
of Issuances.

 

(i)             Issuance
Notice. Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period on which
the conditions set forth in ‎Section 5(a) and Section 5(b) shall have been satisfied, the
Company may exercise its right to request an issuance of Shares by delivering to the Agent an Issuance Notice; provided, however,
that (A) in no event may the Company deliver an Issuance Notice to the extent that (I) the sum of (x) the aggregate
Sales Price of the requested Issuance Amount, plus (y) the aggregate Sales Price of all Shares issued under all previous Issuance
Notices effected pursuant to this Agreement, would exceed the Maximum Program Amount; and (B) prior to delivery of any Issuance
Notice, the period set forth for any previous Issuance Notice shall have expired or been terminated. An Issuance Notice shall be
considered delivered on the Trading Day that it is received by e mail to the persons set forth in Schedule A hereto and confirmed
by the Company by telephone (including a voicemail message to the persons so identified), with the understanding that, with adequate
prior written notice, the Agent may modify the list of such persons from time to time.

 

    18

     

    

 

(ii)            Agent
Efforts. Upon the terms and subject to the conditions set forth in this Agreement, upon the receipt of an Issuance Notice,
the Agent will use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares
with respect to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information specified
in, the Issuance Notice, unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated
in accordance with the terms of this Agreement. For the avoidance of doubt, the parties to this Agreement may modify an Issuance
Notice at any time provided they both agree in writing to any such modification.

 

(iii)            Method
of Offer and Sale. The Shares may be offered and sold (A) in negotiated transactions with the consent of the Company or
(B) by any other method permitted by law deemed to be an “at the market offering” as defined in
Rule 415(a)(4) under the Securities Act, including block transactions, sales made directly on the Principal Market
or sales made into any other existing trading market of the Common Shares. Nothing in this Agreement shall be deemed to
require either party to agree to the method of offer and sale specified in the preceding sentence, and (except as specified
in clause (A) above) the method of placement of any Shares by the Agent shall be at the Agent’s discretion.

 

(iv)            Confirmation
to the Company. If acting as sales agent hereunder, the Agent will provide written confirmation to the Company no later than
the opening of the Trading Day next following the Trading Day on which it has placed Shares hereunder setting forth the number
of shares sold on such Trading Day, the corresponding Sales Price and the Issuance Price payable to the Company in respect thereof.

 

(v)            Settlement.
Each issuance of Shares will be settled on the applicable Settlement Date for such issuance of Shares and, subject to the provisions
of ‎Section 5, on or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically
transfer the Shares being sold by crediting the Agent or its designee’s account at The Depository Trust Company through its
Deposit/Withdrawal At Custodian (DWAC) System, or by such other means of delivery as may be mutually agreed upon by the parties
hereto and, upon receipt of such Shares, which in all cases shall be freely tradable, transferable, registered shares in good deliverable
form, the Agent will deliver, by wire transfer of immediately available funds, the related Issuance Price in same day funds delivered
to an account designated by the Company prior to the Settlement Date. The Company may sell Shares to the Agent as principal at
a price agreed upon at each relevant time Shares are sold pursuant to this Agreement (each, a “Time of Sale”).

 

(vi)            Suspension
or Termination of Sales. Consistent with standard market settlement practices, the Company or the Agent may, upon notice to
the other party hereto in writing (including by verifiable email) or by telephone (confirmed immediately by verifiable email),
suspend any sale of Shares, and the period set forth in an Issuance Notice shall immediately terminate; provided, however, that
(A) such suspension and termination shall not affect or impair either party’s obligations with respect to any Shares
placed or sold hereunder prior to the receipt of such notice; (B) if the Company suspends or terminates any sale of Shares
after the Agent confirms such sale to the Company, the Company shall still be obligated to comply with ‎Section 3(b)(v) with
respect to such Shares; and (C) if the Company defaults in its obligation to deliver Shares on a Settlement Date, the Company
agrees that it will hold the Agent harmless against any loss, claim, damage or expense (including, without limitation, penalties,
interest and reasonable and documented legal fees and expenses), as incurred, arising out of or in connection with such default
by the Company. The parties hereto acknowledge and agree that, in performing its obligations under this Agreement, the Agent may
borrow Common Shares from stock lenders in the event that the Company has not delivered Shares to settle sales as required by subsection
(v) above, and may use the Shares to settle or close out such borrowings. The Company agrees that no such notice shall be
effective against the Agent unless it is made to the persons identified in writing by the Agent pursuant to Section 3(b)(i).

 

    19

     

    

 

(vii)          No
Guarantee of Placement, Etc. The Company acknowledges and agrees that (A) there can be no assurance that the Agent will
be successful in placing Shares; (B) the Agent will incur no liability or obligation to the Company or any other Person if
it does not sell Shares; and (C) the Agent shall be under no obligation to purchase Shares on a principal basis pursuant to
this Agreement, except as otherwise specifically agreed by the Agent and the Company.

 

(viii)         Material
Non-Public Information. Notwithstanding any other provision of this Agreement, the Company and the Agent agree that the Company
shall not deliver any Issuance Notice to the Agent, and the Agent shall not be obligated to place any Shares, during any period
in which the Company is in possession of material non-public information.

 

(c)            Fees.
As compensation for services rendered, the Company shall pay to the Agent, on the applicable Settlement Date, the Selling Commission
for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant to Section 3(b)(vi))
by the Agent deducting the Selling Commission from the applicable Issuance Amount.

 

(d)            Expenses.
The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder
and in connection with the transactions contemplated hereby, including without limitation (i) all expenses incident to the
issuance and delivery of the Shares (including all printing and engraving costs); (ii) all fees and expenses of the registrar
and transfer agent of the Shares; (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance
and sale of the Shares; (iv) all fees and expenses of the Company’s counsel, independent public or certified public
accountants and other advisors; (v) all costs and expenses incurred in connection with the preparation, printing, filing,
shipping and distribution of the Registration Statement
(including financial statements, exhibits, schedules, consents and certificates of experts), the Prospectus, any Free Writing Prospectus
(as defined below) prepared by or on behalf of, used by, or referred to by the Company, and all amendments and supplements thereto,
and this Agreement (it being understood that this clause (v) shall not include any fees and expenses of counsel for Agent);
(vi) all filing fees, attorneys’ fees and expenses incurred by the Company or the Agent in connection with qualifying
or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Shares for offer and
sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Agent, preparing
and printing a “Blue Sky Survey” or memorandum and a “Canadian wrapper”, and any supplements thereto,
advising the Agent of such qualifications, registrations, determinations and exemptions; (vii) the reasonable and documented
fees and disbursements of the Agent’s counsel, including the reasonable and documented fees and expenses of counsel for the
Agent in connection with, FINRA review, if any, and approval of the Agent’s participation in the offering and distribution
of the Shares; (viii) the filing fees incident to FINRA review, if any; and (ix) the fees and expenses associated with
listing the Shares on the Principal Market. The fees and disbursements of Agent’s counsel pursuant to subsections (vi) and
(vii) above shall not exceed (A) $50,000 in connection with execution of this Agreement and (B) $15,000 in connection
with each Triggering Event Date (as defined below) on which the Company is required to provide a certificate pursuant to Section 4(o).

 

    20

     

    

 

Section 4.          ADDITIONAL
COVENANTS

 

The Company covenants
and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere in this Agreement:

 

(a)            Exchange
Act Compliance. During the Agency Period, the Company shall (i) file, on a timely basis, with the Commission all reports
and documents required to be filed under Section 13, 14 or 15 of the Exchange Act in the manner and within the time periods
required by the Exchange Act; and (ii) either (A) include in its quarterly reports on Form 10-Q and its annual reports
on Form 10-K, a summary detailing, for the relevant reporting period, (1) the number of Shares sold through the Agent
pursuant to this Agreement and (2) the net proceeds received by the Company from such sales or (B) prepare a prospectus
supplement containing, or include in such other filing permitted by the Securities Act or Exchange Act (each an “Interim
Prospectus Supplement”), such summary information and, at least once a quarter and subject to this Section 4,
file such Interim Prospectus Supplement pursuant to Rule 424(b) under the Securities Act (and within the time periods
required by Rule 424(b) and Rule 430B under the Securities Act)).

 

(b)            Securities
Act Compliance. After the date of this Agreement, the Company shall promptly advise the Agent in writing (i) of the receipt
of any comments of, or requests for additional or supplemental information from, the Commission; (ii) of the time and date
of any filing of any post-effective amendment to the Registration Statement, any Rule 462(b) Registration Statement or
any amendment or supplement to the Prospectus, any Free Writing Prospectus; (iii) of the time and date that any post-effective
amendment to the Registration Statement or any Rule 462(b) Registration Statement becomes effective; and (iv) of
the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective
amendment thereto, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus or of any
order preventing or suspending the use of any Free Writing Prospectus or the Prospectus, or of any proceedings to remove, suspend
or terminate from listing or quotation the Common Shares from any securities exchange upon which they are listed for trading or
included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission
shall enter any such stop order at any time, the Company will use its reasonable best efforts to obtain the lifting of
such order as soon as practicable. Additionally, the Company agrees that it shall comply with the provisions of Rule 424(b) and
Rule 433, as applicable, under the Securities Act and will use its reasonable efforts to confirm that any filings made by
the Company under such Rule 424(b) or Rule 433 were received in a timely manner by the Commission.

 

    21

     

    

 

(c)            Amendments
and Supplements to the Prospectus and Other Securities Act Matters. If any event shall occur or condition exist as a result
of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a
material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
when the Prospectus is delivered to a purchaser, not misleading, or if in the opinion of the Agent or counsel for the Agent it
is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, including the Securities Act, the Company
agrees (subject to Section 4(d) and Section 4(f)) to promptly prepare, file with the Commission and
furnish at its own expense to the Agent, amendments or supplements to the Prospectus so that the statements in the Prospectus as
so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, be misleading
or so that the Prospectus, as amended or supplemented, will comply with applicable law including the Securities Act. Neither the
Agent’s consent to, or delivery of, any such amendment or supplement shall constitute a waiver of any of the Company’s
obligations under Section 4(d) and Section 4(f). Notwithstanding the foregoing, the Company shall
not be required to file such amendment or supplement if there is no pending Issuance Notice and the Company believes that it is
in its best interests not to file such amendment or supplement.

 

(d)            Agent’s
Review of Proposed Amendments and Supplements. Prior to amending or supplementing the Registration Statement (including any
registration statement filed under Rule 462(b) under the Securities Act) or the Prospectus (excluding any amendment or
supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review,
a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement,
and the Company shall not file or use any such proposed amendment or supplement without the Agent’s prior consent (such consent
not to be unreasonably withheld, conditioned or delayed), and to file with the Commission within the applicable period specified
in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.

 

(e)            Use
of Free Writing Prospectus. Neither the Company nor the Agent has prepared, used, referred to or distributed, or will prepare,
use, refer to or distribute, without the other party’s prior written consent (such consent of the Agent not to be unreasonably
withheld, conditioned or delayed), any “written communication” that constitutes a “free writing prospectus”
as such terms are defined in Rule 405 under the Securities Act with respect to the offering contemplated by this Agreement
(any such free writing prospectus being referred to herein as a “Free Writing Prospectus”).

 

(f)            Free
Writing Prospectuses. The Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed
time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto to be prepared
by or on behalf of, used by, or referred to by the Company and the Company shall not file, use or refer to any proposed free writing
prospectus or any amendment or supplement thereto without the Agent’s consent (such consent not to be unreasonably withheld,
conditioned or delayed). The Company shall furnish to the Agent, without charge, as many copies of any free writing prospectus
prepared by or on behalf of, or used by the Company, as the Agent may reasonably request. If at any time when a prospectus is required
by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of
the Shares (but in any event if at any time through and including the date of this Agreement) there occurred or occurs an event
or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company
conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue
statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances prevailing at that subsequent time, not misleading, the Company shall promptly amend or supplement
such free writing prospectus to eliminate or correct such conflict or so that the statements in such free writing prospectus as
so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances prevailing at such subsequent time, not misleading, as
the case may be; provided, however, that prior to amending or supplementing any such free writing prospectus, the Company shall
furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such
proposed amended or supplemented free writing prospectus and the Company shall not file, use or refer to any such amended or supplemented
free writing prospectus without the Agent’s consent (such consent not to be unreasonably withheld, conditioned or delayed).

 

    22

     

    

 

(g)            Filing
of Agent Free Writing Prospectuses. The Company shall not take any action that would result in the Agent or the Company being
required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared
by or on behalf of the Agent that the Agent otherwise would not have been required to file thereunder.

 

(h)            Copies
of Registration Statement and Prospectus. After the date of this Agreement through the last time that a prospectus is required
by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of
the Shares, the Company agrees to furnish the Agent with copies (which may be electronic copies) of the Registration Statement
and each amendment thereto, and with copies of the Prospectus and each amendment or supplement thereto in the form in which it
is filed with the Commission pursuant to the Securities Act or Rule 424(b) under the Securities Act, both in such quantities
as the Agent may reasonably request from time to time; and, if the delivery of a prospectus is required under the Securities Act
or under the blue sky or securities laws of any jurisdiction at any time on or prior to the applicable Settlement Date for any
period set forth in an Issuance Notice in connection with the offering or sale of the Shares and if at such time any event has
occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact
or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made when such Prospectus is delivered, not misleading, or, if for any other reason it is necessary during such same
period to amend or supplement the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus
in order to comply with the Securities Act or the Exchange Act, to notify the Agent and to request that the Agent suspend offers
to sell Shares (and, if so notified, the Agent shall cease such offers as soon as practicable); and if the Company decides to amend
or supplement the Registration Statement or the Prospectus as then amended or supplemented, to advise the Agent promptly by telephone
(with confirmation in writing) and to prepare and cause to be filed promptly with the Commission an amendment or supplement to
the Registration Statement or the Prospectus as then amended or supplemented that will correct such statement or omission or effect
such compliance; provided, however, that if during such same period the Agent is required to deliver a prospectus in respect of
transactions in the Shares, the Company shall promptly prepare and file with the Commission such an amendment or supplement.

 

    23

     

    

 

(i)             Blue
Sky Compliance. The Company shall cooperate with the Agent and counsel for the Agent to qualify or register the Shares for
sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities
laws of those jurisdictions designated by the Agent, shall comply with such laws and shall continue such qualifications, registrations
and exemptions in effect so long as required for the distribution of the Shares. The Company shall not be required to qualify as
a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where
it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise the Agent
promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Shares for offering,
sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the
issuance of any order suspending such qualification, registration or exemption, the Company shall use its commercially reasonable
efforts to obtain the withdrawal thereof as soon as practicable.

 

(j)             Earnings
Statement. As soon as practicable, the Company will make generally available to its security holders and to the Agent an earnings
statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the
Company occurring after the date of this Agreement which shall satisfy the provisions of Section 11(a) of the Securities
Act and Rule 158 under the Securities Act, provided that the Company will be deemed to have furnished such statement to its
security holders and the Agent to the extent they are filed on EDGAR.

 

(k)            Listing;
Reservation of Shares. (a)  The Company will maintain the listing of the Shares on the Principal Market; and (b) the
Company will reserve and keep available at all times, free of preemptive rights, Shares for the purpose of enabling the Company
to satisfy its obligations under this Agreement.

 

(l)             Transfer
Agent. The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.

 

(m)           Due
Diligence. During the term of this Agreement, the Company will reasonably cooperate with any reasonable due diligence review
conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information
and making available documents and making available telephonically senior corporate officers, during normal business hours, as
the Agent may reasonably request from time to time.

 

(n)            Representations
and Warranties. The Company acknowledges that each delivery of an Issuance Notice and each delivery of Shares on a Settlement
Date shall be deemed to be (i) an affirmation to the Agent that the representations and warranties of the Company contained
in or made pursuant to this Agreement are true and correct as of the date of such Issuance Notice or of such Settlement Date, as
the case may be, as though made at and as of each such date, except as may be disclosed in the Prospectus (including any documents
incorporated by reference therein and any supplements thereto); and (ii) an undertaking that the Company will advise the Agent
if any of such representations and warranties will not be true and correct as of the Settlement Date for the Shares relating to
such Issuance Notice, as though made at and as of each such date (except that such representations and warranties shall be deemed
to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares).

 

    24

     

    

 

(o)            Deliverables
at Triggering Event Dates; Certificates. The Company agrees that on or prior to the date of the first Issuance Notice and,
during the term of this Agreement after the date of the first Issuance Notice, upon:

 

 

(A)           the
filing of the Prospectus or the amendment or supplement of any Registration Statement or Prospectus (other than a prospectus supplement
relating solely to an offering of securities other than the Shares or a prospectus filed pursuant to Section 4(a)(ii)(B)),
by means of a post-effective amendment, sticker or supplement, but not by means of incorporation of documents by reference into
the Registration Statement or Prospectus;

 

(B)            the
filing with the Commission of an annual report on Form 10-K or a quarterly report on Form 10-Q (including any Form 10-K/A
or Form 10-Q/A containing amended financial information or a material amendment to the previously filed annual report on Form 10-K
or quarterly report on Form 10-Q), in each case, of the Company; or

 

(C)            the
filing with the Commission of a current report on Form 8-K of the Company containing amended financial information (other
than information “furnished” pursuant to Item 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item
8.01 of Form 8-K relating to reclassification of certain properties as discontinued operations in accordance with Statement
of Financial Accounting Standards No. 144) that is material to the offering of securities of the Company in the Agent’s
reasonable discretion;

 

(any such event, a
“Triggering Event Date”), the Company shall furnish the Agent (but in the case of clause (C) above only
if the Agent reasonably determines that the information contained in such current report on Form 8-K of the Company is material)
with a certificate as of the Triggering Event Date, in the form and substance satisfactory to the Agent and its counsel, substantially
similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement
and the Prospectus as amended or supplemented, (A) confirming that the representations and warranties of the Company contained
in this Agreement are true and correct, (B) confirming that the Company has performed all of its obligations hereunder to
be performed on or prior to the date of such certificate and as to the matters set forth in Section 5(a)(iii) hereof,
and (C) containing any other certification that the Agent shall reasonably request. The requirement to provide a certificate
under this Section 4(o) shall be waived for any Triggering Event Date occurring at a time when no Issuance Notice
is pending or a suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company delivers
instructions for the sale of Shares hereunder (which for such calendar quarter shall be considered a Triggering Event Date) and
the next occurring Triggering Event Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following
a Triggering Event Date when a suspension was in effect and did not provide the Agent with a certificate under this Section 4(o),
then before the Company delivers the instructions for the sale of Shares or the Agent sells any Shares pursuant to such instructions,
the Company shall provide the Agent with a certificate in conformity with this Section 4(o) dated as of the date
that the instructions for the sale of Shares are issued.

 

    25

     

    

 

(p)            Legal
Opinions. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to
which the Company is obligated to deliver a certificate pursuant to Section 4(o) for which no waiver is applicable
and excluding the date of this Agreement, a negative assurances letter and the written legal opinion of Hughes Hubbard &
Reed LLP, counsel to the Company and McCarter & English, LLP, intellectual property counsel to the Company, each dated
the date of delivery, in form and substance reasonably satisfactory to Agent and its counsel, substantially similar to the form
previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus
as then amended or supplemented. In lieu of such opinions for subsequent periodic filings, in the discretion of the Agent, the
Company may furnish a reliance letter from such counsel to the Agent, permitting the Agent to rely on a previously delivered opinion
letter, modified as appropriate for any passage of time or Triggering Event Date (except that statements in such prior opinion
shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented as of such Triggering Event
Date).

 

(q)            Comfort
Letter. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to
which the Company is obligated to deliver a certificate pursuant to Section 4(o) for which no waiver is applicable
and excluding the date of this Agreement, the Company shall cause Ernst & Young LLP, the independent registered public
accounting firm who has audited the financial statements included or incorporated by reference in the Registration Statement, to
furnish the Agent a comfort letter, dated the date of delivery, in form and substance reasonably satisfactory to the Agent and
its counsel, substantially similar to the form previously provided to the Agent and its counsel; provided, however, that any such
comfort letter will only be required on the Triggering Event Date specified to the extent that it contains financial statements
filed with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into a Prospectus.
If requested by the Agent, the Company shall also cause a comfort letter to be furnished to the Agent within ten (10) Trading
Days of the date of occurrence of any material transaction or event requiring the filing of a current report on Form 8-K containing
material amended financial information of the Company, including the restatement of the Company’s financial statements. The
Company shall be required to furnish no more than one comfort letter hereunder per each filing of an annual report on Form 10-K
or a quarterly report on Form 10-Q.

 

(r)             Secretary’s
Certificate. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date, the Company
shall furnish the Agent a certificate executed by the Secretary of the Company, signing in such capacity, dated the date of delivery
(i) certifying that attached thereto are true and complete copies of the resolutions duly adopted by the Board of Directors
of the Company authorizing the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby
(including, without limitation, the issuance of the Shares pursuant to this Agreement), which authorization shall be in full force
and effect on and as of the date of such certificate, (ii) certifying and attesting to the office, incumbency, due authority
and specimen signatures of each Person who executed this Agreement for or on behalf of the Company, and (iii) containing any
other certification that the Agent shall reasonably request.

 

(s)            Agent’s
Own Account; Clients’ Account. The Company consents to the Agent trading, in compliance with applicable law, in the Common
Shares for the Agent’s own account and for the account of its clients at the same time as sales of the Shares occur pursuant
to this Agreement.

 

    26

     

    

 

(t)             Investment
Limitation. The Company shall not invest, or otherwise use the proceeds received by the Company from its sale of the Shares
in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment
Company Act.

 

(u)            Market
Activities. The Company will not take, directly or indirectly, any action designed to or that might be reasonably expected
to cause or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate
the sale or resale of the Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all
applicable provisions of Regulation M. If the limitations of Rule 102 of Regulation M (“Rule 102”)
do not apply with respect to the Shares or any other reference security pursuant to any exception set forth in Section (d) of
Rule 102, then promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company will, and
shall cause each of its affiliates to, comply with Rule 102 as though such exception were not available but the other provisions
of Rule 102 (as interpreted by the Commission) did apply. The Company shall promptly notify the Agent if it no longer meets
the requirements set forth in Section (d) of Rule 102.

 

(v)            Notice
of Other Sale. Without the written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell,
contract to sell, grant any option to sell or otherwise dispose of any Common Shares or securities convertible into or exchangeable
for Common Shares (other than Shares hereunder), warrants or any rights to purchase or acquire Common Shares, or effect a reverse
stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Common Shares,
during the period beginning on the third Trading Day immediately prior to the date on which any Issuance Notice is delivered to
the Agent hereunder and ending on the third Trading Day immediately following the Settlement Date with respect to Shares sold
pursuant to such Issuance Notice; and will not directly or indirectly enter into any other “at the market”
or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common
Shares (other than the Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Shares,
warrants or any rights to purchase or acquire, Common Shares prior to the termination of this Agreement; provided, however, that
such restrictions will not be required in connection with the Company’s (i) issuance or sale of Common Shares, options
to purchase Common Shares or Common Shares issuable upon the exercise of options or other equity awards pursuant to any employee
or director share option, incentive or benefit plan, share purchase or ownership plan, long-term incentive plan, dividend reinvestment
plan, inducement award under Nasdaq rules or other compensation plan of the Company or its subsidiaries, as in effect on
the date of this Agreement, (ii) issuance or sale of Common Shares issuable upon exchange, conversion or redemption of securities
or the exercise or vesting of warrants, options or other equity awards outstanding at the date of this Agreement, (iii) modification
of any outstanding options, warrants of any rights to purchase or acquire Common Shares, and (iv) issuance or sale of Common
Shares or securities convertible into or exchangeable for Common Shares as consideration for mergers, acquisitions, other business
combinations, joint ventures or strategic alliances occurring after the date of this Agreement which are not used for capital
raising purposes, provided that the aggregate number of Common Shares issued or sold under this subsection (iv) shall not
exceed 5% of the number of Common Shares outstanding immediately prior to giving effect to such sale of issuance.

 

Section 5.          CONDITIONS
TO DELIVERY OF ISSUANCE NOTICES AND TO SETTLEMENT

 

(a)            Conditions
Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent to Sell Shares. The
right of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance
Notice, and the obligation of the Agent to use its commercially reasonable efforts to place Shares during the applicable period
set forth in the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period set forth in
the Issuance Notice, of each of the following conditions:

 

    27

     

    

 

(i)            Accuracy
of the Company’s Representations and Warranties; Performance by the Company. The Company shall have delivered the certificate
required to be delivered pursuant to Section 4(o) on or before the date on which delivery of such certificate
is required pursuant to Section 4(o). The Company shall have performed, satisfied and complied with all covenants,
agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to
such date, including, but not limited to, the covenants contained in ‎Section 4(p), Section 4(q) and
Section 4(r).

 

(ii)            No
Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority
over the matters contemplated hereby that prohibits or directly and materially adversely affects any of the transactions contemplated
by this Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely
affecting any of the transactions contemplated by this Agreement.

 

(iii)           Material
Adverse Changes. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent
there shall not have occurred any Material Adverse Change; and (b) there shall not have occurred any downgrading, nor shall
any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate
the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any “nationally
recognized statistical rating organization” as such term is defined for purposes of Section 3(a)(62) of the Exchange
Act.

 

(iv)           No
Suspension of Trading in or Delisting of Common Shares; Other Events. The trading of the Common Shares (including without limitation
the Shares) shall not have been suspended by the Commission, the Principal Market or FINRA and the Common Shares (including without
limitation the Shares) shall have been approved for listing or quotation on and shall not have been delisted from the Nasdaq Stock
Market, the New York Stock Exchange or any of their constituent markets. There shall not have occurred (and be continuing in the
case of occurrences under clauses (i) and (ii) below) any of the following: (i) trading or quotation in any of the
Company’s securities shall have been suspended or limited by the Commission or by the Principal Market or trading in securities
generally on either the Principal Market shall have been suspended or limited, or minimum or maximum prices shall have been generally
established on any of such stock exchanges by the Commission or the FINRA; (ii) a general banking moratorium shall have been
declared by any of federal or New York, authorities; or (iii) there shall have occurred any outbreak or escalation of national
or international hostilities or any crisis or calamity, or any change in the United States or international financial markets,
or any substantial change or development involving a prospective substantial change in United States’ or international political,
financial or economic conditions, as in the judgment of the Agent is material and adverse and makes it impracticable to market
the Shares in the manner and on the terms described in the Prospectus or to enforce contracts for the sale of securities.

 

    28

     

    

 

(b)            Documents
Required to be Delivered on each Issuance Notice Date. The Agent’s obligation to use its commercially reasonable efforts
to place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the Issuance Notice Date
of a certificate in form and substance reasonably satisfactory to the Agent, executed by the Chief Executive Officer, President
or Chief Financial Officer of the Company, to the effect that all conditions to the delivery of such Issuance Notice shall have
been satisfied as at the date of such certificate (which certificate shall not be required if the foregoing representations shall
be set forth in the Issuance Notice).

 

(c)            No
Misstatement or Material Omission. Agent shall not have advised the Company that the Registration Statement, the Prospectus
or the Times of Sale Information, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent’s
reasonable opinion is material, or omits to state a fact that in the Agent’s reasonable opinion is material and is required
to be stated therein or is necessary to make the statements therein not misleading.

 

(d)            Agent
Counsel Legal Opinion. Agent shall have received from Cooley LLP, counsel for Agent, such opinion or opinions, on or before
the date on which the delivery of the Company counsel legal opinion is required pursuant to Section 4(p), with respect
to such matters as Agent may reasonably require, and the Company shall have furnished to such counsel such documents as they request
for enabling them to pass upon such matters.

 

Section 6.          INDEMNIFICATION
AND CONTRIBUTION

 

(a)            Indemnification
of the Agent. The Company agrees to indemnify and hold harmless the Agent, its officers and employees, and each person, if
any, who controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability
or expense, as incurred, to which the Agent or such officer, employee or controlling person may become subject, under the Securities
Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions
where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), insofar as such
loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon
(i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment
thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission
or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not
misleading; or (ii) any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus
that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act
or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading and to reimburse
the Agent and each such officer, employee and controlling person for any and all expenses (including the reasonable and documented
fees and disbursements of counsel chosen by the Agent) as such expenses are reasonably incurred by the Agent or such officer, employee
or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage,
liability, expense or action; provided, however, that the foregoing indemnity agreement shall not apply to any loss, claim, damage,
liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue
statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company
by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment
or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists
of the information described in subsection (b) below. The indemnity agreement set forth in this ‎Section 6(a) shall
be in addition to any liabilities that the Company may otherwise have.

 

    29

     

    

 

(b)            Indemnification
of the Company, its Directors and Officers. The Agent agrees to indemnify and hold harmless the Company, each of its directors,
each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning
of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Company
or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal
or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold
or at common law or otherwise (including in settlement of any litigation), arises out of or is based upon (i) any untrue statement
or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any
information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission
therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii) any
untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used,
referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any
amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading; but, for each of (i) and
(ii) above, only to the extent arising out of or based upon any untrue statement or alleged untrue statement or omission or
alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly
for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto),
it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information
set forth in the first sentence of ninth paragraph under the caption “Plan of Distribution” in the Prospectus, and
to reimburse the Company and each such director, officer and controlling person for any and all expenses (including the fees and
disbursements of one counsel chosen by the Company) as such expenses are reasonably incurred by the Company or such officer, director
or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage,
liability, expense or action. The indemnity agreement set forth in this Section 6(b) shall be in addition to any
liabilities that the Agent or the Company may otherwise have.

 

    30

     

    

 

(c)            Notifications
and Other Indemnification Procedures. Promptly after receipt by an indemnified party under this ‎Section 6
of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an
indemnifying party under this ‎Section 6, notify the indemnifying party in writing of the commencement thereof,
but the omission so to notify the indemnifying party will not relieve it from any liability which it may have to any indemnified
party for contribution or otherwise than under the indemnity agreement contained in this ‎Section 6 or to the extent
it is not prejudiced as a proximate result of such failure. In case any such action is brought against any indemnified party and
such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to
participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written
notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume
the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, if the defendants in any
such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded
that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of
any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or
additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate
counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified
party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party’s
election so to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will
not be liable to such indemnified party under this Section 6 for any legal or other expenses subsequently incurred
by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed separate
counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall
not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified
parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected
by the indemnified party (in the case of counsel for the indemnified parties referred to in ‎Section 6(a) and
Section 6(b) above), (ii) the indemnifying party shall not have employed counsel satisfactory to the indemnified
party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii) the
indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying
party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid
as they are incurred.

 

(d)            Settlements.
The indemnifying party under this ‎Section 6 shall not be liable for any settlement of any proceeding effected
without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying
party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement
or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party
to reimburse the indemnified party for fees and expenses of counsel as contemplated by Section 6(c) hereof, the
indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if
(i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request; and
(ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the
date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement,
compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any
indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party,
unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on
claims that are the subject matter of such action, suit or proceeding.

 

    31

     

    

 

(e)            Contribution.
If the indemnification provided for in this ‎Section 6 is for any reason held to be unavailable to or otherwise
insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred
to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as
incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as
is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Agent, on the other hand, from
the offering of the Shares pursuant to this Agreement; or (ii) if the allocation provided by clause (i) above is not
permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause
(i) above but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, in connection with
the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant
equitable considerations. The relative benefits received by the Company, on the one hand, and the Agent, on the other hand, in
connection with the offering of the Shares pursuant to this Agreement shall be deemed to be in the same respective proportions
as the total gross proceeds from the offering of the Shares (before deducting expenses) received by the Company bear to the total
commissions received by the Agent. The relative fault of the Company, on the one hand, and the Agent, on the other hand, shall
be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission
or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Agent, on
the other hand, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent
such statement or omission.

 

The amount paid or
payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include,
subject to the limitations set forth in ‎Section 6(c), any legal or other fees or expenses reasonably incurred
by such party in connection with investigating or defending any action or claim. The provisions set forth in ‎Section 6(c) with
respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this ‎Section 6(e);
provided, however, that no additional notice shall be required with respect to any action for which notice has been given under
‎Section 6(c) for purposes of indemnification.

 

The Company and the
Agent agree that it would not be just and equitable if contribution pursuant to this ‎Section 6(e) were determined
by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred
to in this ‎‎Section 6(e).

 

Notwithstanding the
provisions of this ‎‎Section 6(e), the Agent shall not be required to contribute any amount in excess of the
Selling Commission received by the Agent in connection with the offering contemplated hereby. No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was
not guilty of such fraudulent misrepresentation. For purposes of this ‎‎Section 6(e), each officer and employee
of the Agent and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act shall
have the same rights to contribution as the Agent, and each director of the Company, each officer of the Company who signed the
Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange
Act shall have the same rights to contribution as the Company.

 

    32

     

    

 

Section 7.          TERMINATION &
SURVIVAL

 

(a)            Term.
Subject to the provisions of this ‎Section 7, the term of this Agreement shall continue from the date of this Agreement
until the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this ‎Section 7.

 

(b)            Termination;
Survival Following Termination.

 

(i)             Either
party may terminate this Agreement prior to the end of the Agency Period, by giving written notice as required by this Agreement,
upon ten (10) Trading Days’ notice to the other party; provided that, (A) if the Company terminates this Agreement
after the Agent confirms to the Company any sale of Shares, the Company shall remain obligated to comply with ‎Section 3(b)(v) with
respect to such Shares and (B) ‎Section 2, ‎Section 3(d), Section 6, Section 7
and Section 8 shall survive termination of this Agreement. If termination shall occur prior to the Settlement Date
for any sale of Shares, such sale shall nevertheless settle in accordance with the terms of this Agreement.

 

(ii)            In
addition to the survival provision of ‎Section 7(b)(i), the respective indemnities, agreements, representations,
warranties and other statements of the Company, of its officers and of the Agent set forth in or made pursuant to this Agreement
will remain in full force and effect, regardless of any investigation made by or on behalf of the Agent or the Company or any of
its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary
notwithstanding, will survive delivery of and payment for the Shares sold hereunder and any termination of this Agreement.

 

Section 8.          MISCELLANEOUS

 

(a)            Press
Releases and Disclosure. The Company may issue a press release describing the material terms of the transactions contemplated
hereby as soon as practicable following the date of this Agreement, and may file with the Commission a Current Report on Form 8
K, with this Agreement attached as an exhibit thereto, describing the material terms of the transactions contemplated hereby, and
the Company shall consult with the Agent prior to making such disclosures, and the parties hereto shall use all commercially reasonable
efforts, acting in good faith, to agree upon a text for such disclosures that is reasonably satisfactory to all parties hereto.
No party hereto shall issue thereafter any press release or like public statement (including, without limitation, any disclosure
required in reports filed with the Commission pursuant to the Exchange Act) related to this Agreement or any of the transactions
contemplated hereby without the prior written approval of the other party hereto, except as may be necessary or appropriate in
the reasonable opinion of the party seeking to make disclosure to comply with the requirements of applicable law or stock exchange
rules. If any such press release or like public statement is so required, the party making such disclosure shall consult with the
other party prior to making such disclosure, and the parties shall use all commercially reasonable efforts, acting in good faith,
to agree upon a text for such disclosure that is reasonably satisfactory to all parties hereto.

 

    33

     

    

 

(b)            No
Advisory or Fiduciary Relationship. The Company acknowledges and agrees that (i) the transactions contemplated by this
Agreement, including the determination of any fees, are arm’s-length commercial transactions between the Company and the
Agent, (ii) when acting as a principal under this Agreement, the Agent is and has been acting solely as a principal is not
the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (iii) the Agent has not
assumed nor will assume an advisory or fiduciary responsibility in favor of the Company with respect to the transactions contemplated
hereby or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the Company on other
matters) and the Agent does not have any obligation to the Company with respect to the transactions contemplated hereby except
the obligations expressly set forth in this Agreement, (iv) the Agent and its affiliates may be engaged in a broad range of
transactions that involve interests that differ from those of the Company, and (v) the Agent has not provided any legal, accounting,
regulatory or tax advice with respect to the transactions contemplated hereby and the Company has consulted its own legal, accounting,
regulatory and tax advisors to the extent it deemed appropriate.

 

(c)            Research
Analyst Independence. The Company acknowledges that the Agent’s research analysts and research departments are required
to and should be independent from their respective investment banking divisions and are subject to certain regulations and internal
policies, and as such the Agent’s research analysts may hold views and make statements or investment recommendations and/or
publish research reports with respect to the Company or the offering that differ from the views of their respective investment
banking divisions. The Company understands that the Agent is a full service securities firm and as such from time to time, subject
to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short
positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

 

(d)            Notices.
All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties
hereto as follows:

 

If to the Agent:

 

Jefferies LLC

520 Madison Avenue

New York, NY 10022

Facsimile: (646) 786-5719

Attention: General Counsel

 

with a copy (which shall not constitute
notice) to:

 

Cooley LLP

55 Hudson Yards

New York, NY 10001

Attention: Daniel I. Goldberg, Esq.

Facsimile: (212) 479-6275

 

    34

     

    

 

If to the Company:

 

Cyclerion Therapeutics, Inc.

301 Binney Street

Cambridge, MA 02142

Attention: William Huyett

Facsimile: whuyett@cyclerion.com

 

with a copy (which shall not constitute
notice) to:

 

Hughes Hubbard & Reed
LLP

One Battery Park Plaza, 12th
Floor

New York, NY 10004-1482

Attention: Gary J. Simon

Email: gary.simon@hugheshubbard.com

 

Any party hereto may change the address
for receipt of communications by giving written notice to the others in accordance with this Section 8(d).

 

(e)            Successors.
This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers
and directors and controlling persons referred to in Section 6, and in each case their respective successors, and no
other person will have any right or obligation hereunder. The term “successors” shall not include any purchaser of
the Shares as such from the Agent merely by reason of such purchase.

 

(f)            Partial
Unenforceability. The invalidity or unenforceability of any Article, Section, paragraph or provision of this Agreement shall
not affect the validity or enforceability of any other Article, Section, paragraph or provision hereof. If any Article, Section,
paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to
be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.

 

(g)            Governing
Law Provisions. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New
York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based
upon this Agreement or the transactions contemplated hereby may be instituted in the federal courts of the United States of America
located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the
Borough of Manhattan in the City of New York (collectively, the “Specified Courts”), and each party irrevocably
submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such
court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process,
summons, notice or document by mail to such party’s address set forth above shall be effective service of process for any
suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to
the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and
agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been
brought in an inconvenient forum.

 

    35

     

    

 

(h)            General
Provisions. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written
or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This
Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument, and may be delivered by facsimile transmission or by electronic delivery of a
portable document format (PDF) file (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform
Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com). This Agreement
may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may
be waived unless waived in writing by each party whom the condition is meant to benefit. The Article and Section headings
herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.

 

[Signature Page Immediately Follows]

 

    36

     

    

 

If the foregoing is
in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon
this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms.

 

	 	Very truly yours,
	 	 
	 	CYCLERION THERAPEUTICS, INC.
	 	 
	 	 
	 	By:	/s/ William I.
    Huyett                 
	 	 	Name:	 William I.
    Huyett 
	 	 	Title:	Chief Financial Officer

 

The foregoing Agreement
is hereby confirmed and accepted by the Agent in New York, New York as of the date first above written.

 

	JEFFERIES LLC	 
	 	 
	 	 
	By:	/s/ Michael Magarro	 
	 	Name:	Michael Magarro	 
	 	Title:	Managing Director	 

 

    

     

    

 

EXHIBIT A

 

ISSUANCE NOTICE

 

[Date]

 

Jefferies LLC

520 Madison Avenue

New York, New York 10022

 

Attn: [__________]

 

Reference is made to the Open Market
Sale AgreementSM between Cyclerion Therapeutics, Inc. (the “Company”) and Jefferies LLC
(the “Agent”) dated as of September 3, 2020. The Company confirms that all conditions to the delivery of
this Issuance Notice are satisfied as of the date hereof.

 

Date of Delivery of Issuance Notice (determined pursuant to
Section 3(b)(i)):

 

_______________________

 

Issuance Amount (equal to the total Sales Price for such Shares):

 

	 	$
	 
	Number of days in selling period:	 
	 
	First date of selling period:	 
	 
	Last date of selling period:	 
	 
	Settlement Date(s) if other than standard T+2 settlement:	 
	 	 

 

Floor Price Limitation (in no event less than $1.00 without
the prior written consent of the Agent, which consent may be withheld in the Agent’s sole discretion): $ ____ per share

 

	Comments:	 

 

	 	 
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

    

     

    

 

Schedule A

 

Notice Parties

 

The Company

 

[●]

 

The Agent

 

[●]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]